News | Atherectomy Devices | February 08, 2017

LIBERTY 360 Study Demonstrates Sustained Benefit of Endovascular Intervention in Lower Extremity PAD

Following positive 30-day results, six-month data from the LIBERTY 360° study showed patients in all Rutherford Classes maintained improvement in PAD symptoms and quality of life

CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD

February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET), Feb. 4-8 in Hollywood, Fla. The study is evaluating the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in treating patients with symptomatic lower extremity peripheral artery disease (PAD).

Physicians were able to use any U.S. Food and Drug Administration (FDA)-approved device, including CSI’s Diamondback 360 peripheral orbital atherectomy system. Findings continue to demonstrate that PVI can be successful in treating patients in all Rutherford Classes and suggest that “watchful waiting” for patients in Rutherford Class 2-3 and “primary amputation” for patients in Rutherford Class 6 may not be necessary.

Six-month study outcomes were presented at ISET by William Gray, M.D., of Main Line Health, Wynnewood, Pa. Additional authors on the abstract included Jihad Mustapha, M.D., of Metro Health Hospital, Wyoming, Mich.; George L. Adams, M.D., of Rex Healthcare, Raleigh, N.C.; Gary Ansel, M.D., of OhioHealth in Columbus, Ohio; and Michael Jaff, DO, president, Newton-Wellesley Hospital and professor of medicine, Harvard Medical School.

Some of the key six-month analysis conclusions discussed were:

  • Findings suggest that on average PVI can restore Rutherford 4-5 patients with critical limb ischemia (CLI) status (e.g. limb pain at rest, cold and/or numbness in feet, open or non-healing wounds on toes or foot) to moderate claudicant status (e.g. limb pain during movement); and
  • Through six months, these data demonstrate on average PAD patients (Rutherford 2-6) post-PVI have maintained good outcomes and positive changes in Rutherford classification

Change in Rutherford Classification Following Endovascular Intervention

 
Baseline
30 Days
6 Months

RC 2-3
2.8
1.3
1.4

RC 4-5
4.5
3.1
2.3

RC 6
6.0
5.5
4.6

 Table 1: All Rutherford Classes show improvement in RC from baseline to 30 days. RC4-5 and RC6 show continued improvement from 30 days to 6 months while RC2-3 maintains improvement at 6 months.

Said Gray, “Following endovascular intervention, we saw a marked improvement across all Rutherford Classes at six months: Rutherford 4-5 and Rutherford 6 patients showed continued improvement from 30 days to six months, while Rutherford 2-3 patients maintained improvement at six months. We also saw a high freedom from major adverse events across all classes. This suggests that endovascular intervention is an alternative treatment option in place of watchful waiting or even primary amputation.”

 
 

 
Rutherford Classification

RC 2-3
RC 4-5
RC 6

Freedom from (FF) MAE (6-month)
92.6%
81.2%
73.7%

FF Major Amputation
99.8%
96.8%
87.1%

FF Target Vessel Revascularization (TVR)
93.0%
83.1%
85.1%

FF Death
97.1%
95.3%
85.1%

Table 2: High freedom from MAEs at 6 months across all Rutherford Classes. Kaplan-Meier method used to estimate event-free rates. MAE defined as death (≤30 days after the procedure), major amputation of the target limb, and TVR.

According to VascuQoL, a patient-reported, PAD-specific health-related quality of life questionnaire, patients in the LIBERTY 360° study reported improved quality of life across all Rutherford Classes, including such measures as physical activity, symptoms and pain.

During a concurrent session at ISET, Mustapha highlighted the importance the LIBERTY 360° Rutherford 6 data will have on the endovascular field. He stated, “LIBERTY 360° is novel in that it addresses all Rutherford Classes, including Class 6, representing some of the most challenging and life-threatening PAD cases. Six-month data suggests that these patients can be treated successfully with endovascular interventions – a significant step in establishing a new standard of care for this difficult-to-treat population.”

Additionally it was shared that the recently released “2016 Guidelines on the Management of Patients with PAD” from the American Heart Association (AHA)/American College of Cardiology (ACC) support this data, stating:

  • Revascularization is a reasonable treatment option for patients with lifestyle-limiting claudication and an inadequate response to medical management and exercise; and
  • An evaluation for revascularization options should be performed by an interdisciplinary care team before amputation in the patient with CLI.

For more information: www.iset.org

Related Content

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Arterial Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
News | Venous Therapies| April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease
News | Cardiac Diagnostics| April 25, 2017
Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack and death in people with...
Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System
News | Robotic Systems| April 24, 2017
A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of...
CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices| April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...
Overlay Init